Today: 7 February 2026
Subscribe

Mateusz Kaczmarek

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Nuburu Stock Soars on New Defense Deals – Price, News, and Expert Analysis

Nuburu Stock Soars on New Defense Deals – Price, News, and Expert Analysis

Sources: Official press releases and filings (BusinessWire/NYSE American) provide details of the acquisitions and leadership changes businesswire.com businesswire.com. Financial and stock commentary from TechStock² (ts2.tech) and media outlets add analysis: for example, TechStock² notes the Orbit deal spurred a 30% share jump ts2.tech, while CoinCentral highlights real-contract revenue for Nuburu coincentral.com. Stock market sites confirm the price moves benzinga.com ts2.tech and summarize the company’s historic financials (tiny revenues, large losses) ts2.tech. All sources together paint a picture of a penny-stock rocket fueled by defense-tech hype, yet shadowed by risk.
22 October 2025
····
AI Buzz Lifts Pegasystems Stock – Pega Shares Soar on Strong Q3 Results and New Platform Launch

AI Buzz Lifts Pegasystems Stock – Pega Shares Soar on Strong Q3 Results and New Platform Launch

Earnings Beat Propels Stock: On October 21, Pega reported Q3 FY2025 results that handily beat forecasts. Quarterly revenue hit $381.4 million, up 17% from a year ago and above the $351M consensus, and adjusted EPS jumped to $0.30 (versus ~ $0.20 expected) stocktwits.com. CEO Alan Trefler emphasized that Pega’s AI strategy – especially its Blueprint and GenAI tools – is “resonating deeply with clients, prospects, and partners, unlocking new levels of speed, predictability, and scale in enterprise applications” businesswire.com. COO/CFO Ken Stillwell noted “strong sales performance powered by Pega Blueprint” and said the company generated $347M in operating cash flow
22 October 2025
···
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes Buyout Sparks Rally in AVDL Stock On Oct. 22, 2025, Alkermes announced it would acquire Avadel for $18.50 cash per share plus a $1.50 contingent value right (CVR) tied to an FDA approval for idiopathic hypersomnia, valuing the deal at up to $2.1 billion prnewswire.com. The all-cash offer represents roughly a 12% premium to Avadel’s recent trading range. Avadel CEO Greg Divis hailed the terms as “a compelling outcome for our shareholders” prnewswire.com, while Alkermes CEO Richard Pops said the deal is “a pivotal step” to accelerate Alkermes’ entry into the sleep-medicine market prnewswire.com. Avadel’s board and Alkermes’ board have
22 October 2025
····
Amphenol (APH) Stock Soars on Record Q3 and AI Boom – Analysts Target $150

Amphenol (APH) Stock Soars on Record Q3 and AI Boom – Analysts Target $150

Amphenol’s stock (NYSE: APH) has erupted this October amid record results and AI-driven demand. The connectors-and-sensors maker is capitalizing on the tech boom. Record-Breaking Q3 Results and Guidance Amphenol’s Q3 2025 results (announced Oct 22) were truly outstanding. Sales hit $6.2 billion – up 53% from a year ago – and adjusted EPS was $0.93 (+86% YoY) businesswire.com, far above analysts’ $0.79 estimate. CEO R. Adam Norwitt said they “closed Q3 with record sales and Adjusted EPS, both significantly exceeding the high end of our guidance” businesswire.com. Operating margin hit a record 27.5% and cash flow was robust ($1.5B). In short, the
22 October 2025
·····
Applied DNA (BNBX) Stock Surges on $58M Binance BNB Crypto Bet; New Ticker Takes Effect

Applied DNA (BNBX) Stock Surges on $58M Binance BNB Crypto Bet; New Ticker Takes Effect

Recent Market Performance Applied DNA’s share price has been extremely volatile amid its strategic shifts. According to market data, BNBX closed at $3.42 on Oct. 21 (down 2.0% that day) marketscreener.com. It then jumped after hours on Oct. 22 with news of the PIPE closing, trading around $4.49 by 8:43 AM EDT on Oct. 22 benzinga.com. This recent pop follows a 31.62% surge on Oct. 6 when Nasdaq officially changed its symbol to BNBX nasdaq.com. Earlier in October the stock briefly spiked near $5.85 (intraday high) on Oct. 6 tipranks.com. In summary, BNBX has climbed from the low-$3’s to the mid-$4’s over the past week, reflecting
22 October 2025
···
Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know

Stock Performance & Analyst Sentiment Arcturus stock had been riding a wave of positive sentiment through October 2025. On Oct 21 it closed at $23.16 – its highest level in a year marketbeat.com – following stronger-than-expected Q2 results (earnings beat and record revenue). However, on Oct 22 the company’s interim cystic fibrosis data triggered a dramatic sell-off. Investing.com reported that ARCT fell about 50% as investors digested the mixed news ng.investing.com. By pre-market trading the next day it was down over 60% at roughly $9 benzinga.com. MarketBeat confirmed that Guggenheim downgraded the stock to Neutral on Oct 22 marketbeat.com. Overall,
22 October 2025
····
Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Beneficient (BENF) Stock Skyrockets 64% After CEO Converts $52M Preferred into Common

Benficient stock (NASDAQ: BENF) closed Oct 21 at ~$0.49 and jumped ~64% to ~$0.80 after hours when Chairman Thomas O. Hicks and Interim CEO James Silk converted $52.6 M of preferred units into Class A shares investing.com benzinga.com. The company is racing to meet Nasdaq’s listing rules (min. equity $35 M or $1 bid price). Q1 FY2026 results (ended 6/30/25) showed heavy losses (GAAP net loss $7.19/share) but CEO Silk emphasized cost cuts and new capital deals to rebuild cash globenewswire.com scr.zacks.com. Zacks maintains a $2.00 price target, implying ~300% upside scr.zacks.com, though ChartMill notes serious financial weakness (fundamental rating 1/10) chartmill.com.
22 October 2025
····
Vicor Stock Skyrockets to 52-Week High After Blockbuster Q3 and AI Licensing Boom

Vicor Stock Skyrockets to 52-Week High After Blockbuster Q3 and AI Licensing Boom

Vicor Corporation (NASDAQ: VICR) shares surged after its Oct. 21 Q3 report, reaching ~$67.82 intraday on Oct. 21 (vs ~$58 the prior close) Marketbeat. The stock is up roughly 30–35% year-to-date (fell to ~$38 low in 2024) and opened Oct 22 near $65–66. Q3 revenue was $110.4 M (up 18.5% YOY) and EPS $0.63, crushing analyst expectations Investing Marketbeat. Analyst firms (Craig-Hallum, Needham) upgraded VICR to Buy with ~$90 price targets, citing strong growth in high-margin IP licensing and next-gen power products Gurufocus Intellectia. Investors are excited by Vicor’s role in AI and data-center power (48V and 800V systems), its recently announced ~$300 M licensing
22 October 2025
·····
AST SpaceMobile Stock Shoots for the Stars – Verizon Deal and Satellite Breakthroughs Ignite 300% Rally

AST SpaceMobile Stock Shoots for the Stars – Verizon Deal and Satellite Breakthroughs Ignite 300% Rally

Stock Price and Recent Performance AST SpaceMobile’s stock has been one of 2025’s hottest stories. After trading around $30 in late 2024, ASTS rallied over 300% this year on a wave of positive news ts2.tech ts2.tech. In early October the stock broke out of the $40s on back-to-back ~16% jumps ts2.tech, hitting all-time highs above $74.77 ts2.tech (and briefly ~$99 on Oct 17 ts2.tech). This month’s catalyst was a partnership announcement with Verizon, which helped ASTS reach an intraday record near $100 ts2.tech. However, volatility has emerged: a dilutive share offering in early October caused a 6% pullback ts2.tech, and
22 October 2025
···
Will SBEV Pop or Flop? Splash Beverage Group Stock Surges on Big Deals – Analysts Weigh In

Will SBEV Pop or Flop? Splash Beverage Group Stock Surges on Big Deals – Analysts Weigh In

Stock Price and Performance Splash Beverage Group (NASDAQ: SBEV) stock has seen dramatic swings in 2025. After trading under $1 for much of early 2025, the shares climbed steeply in the spring, peaking above $13.50. By late October however, SBEV sits around $1.9, down significantly from the highs. Year-to-date it’s up roughly 70%, but this masks wild volatility: for example, a single day move of -22% on April 7 (when NYSE compliance issues hit) and a +38% jump on June 26 (when the Costa Rica water deal was announced) can be seen in the trading record. Chart snippet: FinViz data
22 October 2025
····
VSee Health (VSEE) Stock Skyrockets 75% on $10M Hospital Teleradiology Contract

VSee Health (VSEE) Stock Skyrockets 75% on $10M Hospital Teleradiology Contract

Teleradiology Contract Ignites Stock Rally On Oct. 21 VSee Health (NASDAQ: VSEE) stunned the market by announcing a landmark teleradiology services agreement with a major Level-1 trauma hospital system. The multi-year deal – which began service in June – is valued at roughly $10 million over two years, with additional $5+ million in potential bonuses for meeting volume targets streetinsider.com financialcontent.com. Management says it will double the company’s annual recurring revenue, a milestone that co-CEO Dr. Imo Aisiku hailed as “just the beginning.” In a press statement he called the deal “a game-changer for VSee Health and our shareholders,” saying
22 October 2025
··
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific (NYSE:BSX) posted reported net income of $755 M ($0.51/share GAAP) and adjusted EPS of $0.75 timesunion.com chartmill.com, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” prnewswire.com, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago prnewswire.com. Importantly, organic (same-currency) revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 investing.com, reflecting strong demand for its interventional cardiology and MedSurg devices. Analysts highlighted that every major segment beat. The cardiovascular
22 October 2025
····
1 … 110 111 112 113 114 … 233

Stock Market Today

Westpac share price slides after ASX rout; investors brace for next week’s WBC update

Westpac share price slides after ASX rout; investors brace for next week’s WBC update

7 February 2026
Westpac shares fell 1.2% to A$39.43 Friday as the S&P/ASX 200 dropped 2% amid broad selling. The bank is set to roll out Microsoft 365 Copilot to 35,000 staff after a pilot last year. Investors are watching for signs of loan growth and credit quality ahead of Westpac’s first-quarter update on Feb. 13. The Reserve Bank of Australia raised its cash rate to 3.85% this week.
ANZ share price fell Friday — here’s what to watch before the ASX reopens

ANZ share price fell Friday — here’s what to watch before the ASX reopens

7 February 2026
ANZ shares closed at A$37.01 on Friday, down 1.52% as the S&P/ASX 200 fell 2% and nearly $70 billion was wiped from the market. The Reserve Bank of Australia raised its cash rate by 0.25 points to 3.85%, prompting ANZ to lift variable home loan rates from Feb. 13. ANZ announced a new Salesforce-based AI CRM rollout and a board change effective Feb. 8. Investors await ANZ’s first-quarter update on Feb. 12.
Go toTop